Am J Physiol Cell Physiol Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Cell Physiol 290: C577-C582, 2006. First published September 28, 2005; doi:10.1152/ajpcell.00434.2005
0363-6143/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/2/C577    most recent
00434.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Assereto, S.
Right arrow Articles by Minetti, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Assereto, S.
Right arrow Articles by Minetti, C.

MUSCLE CELL BIOLOGY AND CELL MOTILITY

Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment

Stefania Assereto,1,* Silvia Stringara,1,* Federica Sotgia,1,2 Gloria Bonuccelli,1,2 Aldobrando Broccolini,3 Marina Pedemonte,1 Monica Traverso,1 Roberta Biancheri,1 Federico Zara,1 Claudio Bruno,1 Michael P. Lisanti,1,2 and Carlo Minetti1

1Muscular and Neurodegenerative Disease Unit, University of Genoa and G. Gaslini Pediatric Institute, Genoa, Italy; 2Departments of Molecular Pharmacology and Medicine, The Albert Einstein College of Medicine, Bronx, New York; and 3Neurological Unit, Catholic University, Rome, Italy

Submitted 26 August 2005 ; accepted in final form 22 September 2005

In this report, we have developed a novel method to identify compounds that rescue the dystrophin-glycoprotein complex (DGC) in patients with Duchenne or Becker muscular dystrophy. Briefly, freshly isolated skeletal muscle biopsies (termed skeletal muscle explants) from patients with Duchenne or Becker muscular dystrophy were maintained under defined cell culture conditions for a 24-h period in the absence or presence of a specific candidate compound. Using this approach, we have demonstrated that treatment with a well-characterized proteasome inhibitor, MG-132, is sufficient to rescue the expression of dystrophin, {beta}-dystroglycan, and {alpha}-sarcoglycan in skeletal muscle explants from patients with Duchenne or Becker muscular dystrophy. These data are consistent with our previous findings regarding systemic treatment with MG-132 in a dystrophin-deficient mdx mouse model (Bonuccelli G, Sotgia F, Schubert W, Park D, Frank PG, Woodman SE, Insabato L, Cammer M, Minetti C, and Lisanti MP. Am J Pathol 163: 1663–1675, 2003). Our present results may have important new implications for the possible pharmacological treatment of Duchenne or Becker muscular dystrophy in humans.

muscular dystrophy; membrane proteins; MG-132


Address for reprint requests and other correspondence: C. Minetti, Unità Operativa Malattie Muscolari e Neurodegenerative, Università di Genova, Istituto Giannina Gaslini, Largo Gaslini 5, 16147 Genoa, Italy (e-mail: minettic{at}unige.it), or M. P. Lisanti, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461-1926 (e-mail: lisanti{at}aecom.yu.edu)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.